Enliven initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Enliven Therapeutics with a Buy rating and $37 price target. Enliven is an emerging biotech company developing next generation precision-oriented small molecules for validated targets in unmet needs for both solid and liquid tumor indications, the analyst tells investors in a research note. The firm says ELVN-001 and ELVN-002 have already shown early signs of clinical promise. It sees multiple near- and medium-term clinical data catalysts for the shares.